198 related articles for article (PubMed ID: 29641318)
1. Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions.
Kassner U; Hollstein T; Grenkowitz T; Wühle-Demuth M; Salewsky B; Demuth I; Dippel M; Steinhagen-Thiessen E
Hum Gene Ther; 2018 Apr; 29(4):520-527. PubMed ID: 29641318
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.
Gaudet D; Stroes ES; Méthot J; Brisson D; Tremblay K; Bernelot Moens SJ; Iotti G; Rastelletti I; Ardigo D; Corzo D; Meyer C; Andersen M; Ruszniewski P; Deakin M; Bruno MJ
Hum Gene Ther; 2016 Nov; 27(11):916-925. PubMed ID: 27412455
[TBL] [Abstract][Full Text] [Related]
3. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.
Haddley K
Drugs Today (Barc); 2013 Mar; 49(3):161-70. PubMed ID: 23527320
[TBL] [Abstract][Full Text] [Related]
4. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency.
Scott LJ
Drugs; 2015 Feb; 75(2):175-82. PubMed ID: 25559420
[TBL] [Abstract][Full Text] [Related]
5. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.
Gaudet D; de Wal J; Tremblay K; Déry S; van Deventer S; Freidig A; Brisson D; Méthot J
Atheroscler Suppl; 2010 Jun; 11(1):55-60. PubMed ID: 20427244
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.
Ferreira V; Twisk J; Kwikkers K; Aronica E; Brisson D; Methot J; Petry H; Gaudet D
Hum Gene Ther; 2014 Mar; 25(3):180-8. PubMed ID: 24299335
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.
Gaudet D; Méthot J; Déry S; Brisson D; Essiembre C; Tremblay G; Tremblay K; de Wal J; Twisk J; van den Bulk N; Sier-Ferreira V; van Deventer S
Gene Ther; 2013 Apr; 20(4):361-9. PubMed ID: 22717743
[TBL] [Abstract][Full Text] [Related]
8. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients.
Carpentier AC; Frisch F; Labbé SM; Gagnon R; de Wal J; Greentree S; Petry H; Twisk J; Brisson D; Gaudet D
J Clin Endocrinol Metab; 2012 May; 97(5):1635-44. PubMed ID: 22438229
[TBL] [Abstract][Full Text] [Related]
9. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency.
Burnett JR; Hooper AJ
Curr Opin Mol Ther; 2009 Dec; 11(6):681-91. PubMed ID: 20072945
[TBL] [Abstract][Full Text] [Related]
10. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency.
Wierzbicki AS; Viljoen A
Expert Opin Biol Ther; 2013 Jan; 13(1):7-10. PubMed ID: 23126631
[TBL] [Abstract][Full Text] [Related]
11. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
Steinhagen-Thiessen E; Stroes E; Soran H; Johnson C; Moulin P; Iotti G; Zibellini M; Ossenkoppele B; Dippel M; Averna MR;
Atherosclerosis; 2017 Jul; 262():146-153. PubMed ID: 28284702
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for lipoprotein lipase deficiency.
Gaudet D; Méthot J; Kastelein J
Curr Opin Lipidol; 2012 Aug; 23(4):310-20. PubMed ID: 22691709
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
Salmon F; Grosios K; Petry H
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
[TBL] [Abstract][Full Text] [Related]
15. Severe hypertriglyceridaemia and pancreatitis in a patient with lipoprotein lipase deficiency based on mutations in lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) genes.
Koopal C; Bemelmans R; Marais AD; Visseren FL
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30948399
[TBL] [Abstract][Full Text] [Related]
16. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.
Ross CJ; Twisk J; Meulenberg JM; Liu G; van den Oever K; Moraal E; Hermens WT; Rip J; Kastelein JJ; Kuivenhoven JA; Hayden MR
Hum Gene Ther; 2004 Sep; 15(9):906-19. PubMed ID: 15353045
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.
Nierman MC; Rip J; Twisk J; Meulenberg JJ; Kastelein JJ; Stroes ES; Kuivenhoven JA
Neth J Med; 2005 Jan; 63(1):14-9. PubMed ID: 15719847
[TBL] [Abstract][Full Text] [Related]
18. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.
Ross CJ; Twisk J; Bakker AC; Miao F; Verbart D; Rip J; Godbey T; Dijkhuizen P; Hermens WT; Kastelein JJ; Kuivenhoven JA; Meulenberg JM; Hayden MR
Hum Gene Ther; 2006 May; 17(5):487-99. PubMed ID: 16716106
[TBL] [Abstract][Full Text] [Related]
19. A novel substitution at the translation initiator codon (ATG-->ATC) of the lipoprotein lipase gene is mainly responsible for lipoprotein lipase deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis.
Yu XH; Zhao TQ; Wang L; Liu ZP; Zhang CM; Chen R; Li L; Liu G; Hu WC
Biochem Biophys Res Commun; 2006 Mar; 341(1):82-7. PubMed ID: 16431216
[TBL] [Abstract][Full Text] [Related]
20. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen.
den Hollander B; Brands MM; Nijhuis IJM; Doude van Troostwijk LJAE; van Essen P; Hofsteenge GH; Koot BG; Müller AR; Tseng LA; Stroes ESG; van de Ven PM; Wiegman A; van Karnebeek CDM
Mol Genet Metab; 2024 May; 142(1):108347. PubMed ID: 38401382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
